Compare QXO & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QXO | TWST |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 9.2B |
| IPO Year | 2014 | 2018 |
| Metric | QXO | TWST |
|---|---|---|
| Price | $11.50 | $120.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | $24.06 | ★ $168.25 |
| AVG Volume (30 Days) | ★ 20.6M | 2.4M |
| Earning Date | 11-17-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | $54,516,941.00 | ★ $376,572,000.00 |
| Revenue This Year | $104.99 | $21.17 |
| Revenue Next Year | $32.26 | $20.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.19 | 20.32 |
| 52 Week Low | $10.04 | $23.30 |
| 52 Week High | $27.61 | $219.71 |
| Indicator | QXO | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 38.85 |
| Support Level | $11.14 | $79.90 |
| Resistance Level | $12.71 | $155.44 |
| Average True Range (ATR) | 0.65 | 15.43 |
| MACD | 0.19 | -3.39 |
| Stochastic Oscillator | 50.54 | 4.11 |
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.